← All trials
NCT06564844
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2024
- Primary completion
- Nov 3, 2031
- Completion date
- Feb 1, 2035
- First posted
- Aug 21, 2024
- Last posted
- Aug 21, 2024
- Enrollment
- 660
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Daiichi SankyoCollaborator
- Universidad Autonoma de BarcelonaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.